Skip to content

menu

Rothwell, Figg, Ernst & Manbeck, P.C. logo
Current Page:HomeAboutContact
RF EMerge logo

A Resource for Innovators

Topics

GuidanceTrends & AnalysisLegal DevelopmentsSubscribe

Featured

Plant Based Vegan Food for a Healthy Lifestyle

Foodtech Pioneer Impossible Foods Sues Competitor Motif for Patent Infringement

By Sheena Wang on May 17, 2022

Background

The food tech industry has been rapidly growing in recent years with the rise…

Continue Reading Foodtech Pioneer Impossible Foods Sues Competitor Motif for Patent Infringement

Arbutus and Genevant Sue Moderna in First Significant Patent Infringement Lawsuit in the mRNA Space

By Dan Shores on March 27, 2022

In the first major patent infringement lawsuit in the mRNA space, on February 28, 2022…

Continue Reading Arbutus and Genevant Sue Moderna in First Significant Patent Infringement Lawsuit in the mRNA Space
Abstract Genetics Disease

PTAB Sides with Broad in Patent Dispute over CRISPR Gene Editing of Eukaryotic Cells

By Xiaoban Xin on March 7, 2022

On February 28, 2022, the Patent Trial and Appeal Board (PTAB) issued a decision in…

Continue Reading PTAB Sides with Broad in Patent Dispute over CRISPR Gene Editing of Eukaryotic Cells
Latest
RF

Human Creativity v. Machine Autonomy in Identifying Copyright Authors of Generative NFTs

By Jennifer Maisel on February 23, 2022
Posted in Uncategorized

Generative content is having a moment in the form of non-fungible tokens (NFTs) powered by blockchain platforms.  Continued investment and…
Continue Reading Human Creativity v. Machine Autonomy in Identifying Copyright Authors of Generative NFTs

Delaware Judge Denies Sarepta Protection Under Hatch-Waxman “Safe Harbor”

By Dan Shores on January 5, 2022
Posted in Featured, Legal Developments

On January 4, 2022, Judge Andrews from the United States District Court for the District of Delaware denied Sarepta Therapeutics,…
Continue Reading Delaware Judge Denies Sarepta Protection Under Hatch-Waxman “Safe Harbor”

mRNA Patent and Competitive Landscape: 2021 Year in Review and 2022 Outlook

By Dan Shores, Vivian Tian & Sheena Wang on January 3, 2022
Posted in Featured, Trends & Analysis

In April of 2021, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market.
Continue Reading mRNA Patent and Competitive Landscape: 2021 Year in Review and 2022 Outlook

Patent And Trademark Office Headquarters

Laying Down the [Trademark] Law – The USPTO Signals Stricter Enforcement to Come

By Malissa Magiera on December 21, 2021
Posted in Legal Developments

On June 8, 2021, the USPTO issued an Order to Show Cause to Shenzhen Huanyee Intellectual Property Co., Ltd. (“the…
Continue Reading Laying Down the [Trademark] Law – The USPTO Signals Stricter Enforcement to Come

Three (3) Initial Considerations for Entrepreneurial Faculty, Researchers, Post-Docs, and Graduate Students

By Michael Thompson & Dan Shores on November 17, 2021
Posted in Featured, Guidance

Introduction

Universities and certain colleges in the United States (US) spend billions of dollars on research and development (R&D) each…
Continue Reading Three (3) Initial Considerations for Entrepreneurial Faculty, Researchers, Post-Docs, and Graduate Students

Alphabet Dives Further Into AI-Driven Drug Discovery

By Dan Shores on November 5, 2021
Posted in Featured, Trends & Analysis

Google’s parent company Alphabet announced the launch of a new company this week dedicated to applying deep learning methods to…
Continue Reading Alphabet Dives Further Into AI-Driven Drug Discovery

Vertex and Mammoth Biosciences Ink $700M Deal for Ultra-Small CRISPR Systems

By Caitlin Wilmot on October 28, 2021
Posted in Featured, Trends & Analysis

Vertex Pharmaceuticals and Mammoth Biosciences, a Brisbane, California-based genetic research company, announced a new collaboration for the development of in …
Continue Reading Vertex and Mammoth Biosciences Ink $700M Deal for Ultra-Small CRISPR Systems

Radiotherapy Symbol

Pfizer and Voyager Agree to Develop Neurologic and Cardiovascular Gene Therapies Valued at up to $630 Million

By Xiaoban Xin on October 7, 2021
Posted in Featured, Legal Developments

On October 6, 2021, Voyager Therapeutics and Pfizer entered into a license option agreement, which allows Pfizer to exercise options…
Continue Reading Pfizer and Voyager Agree to Develop Neurologic and Cardiovascular Gene Therapies Valued at up to $630 Million

DNA Sequencing Data Processing Genetic Genomic Analysis

Abbvie and Regenexbio Agree to Develop and Commercialize Eye Disease Gene Therapy

By Xiaoban Xin on September 14, 2021
Posted in Featured, Legal Developments

On September 13, 2021, Regenxbio, a Maryland biotech company, and AbbVie announced that they have entered an agreement to develop…
Continue Reading Abbvie and Regenexbio Agree to Develop and Commercialize Eye Disease Gene Therapy

Crispr - gene editing

Moderna’s Next Steps: Spikevax Today, Gene Editing Tomorrow

By Vivian Tian on August 16, 2021
Posted in Featured, Trends & Analysis

Following the successful development (and financial success) of its mRNA vaccine, biotech company Moderna is now looking to expand into…
Continue Reading Moderna’s Next Steps: Spikevax Today, Gene Editing Tomorrow

Post navigation

Older Posts 
Rothwell, Figg, Ernst & Manbeck, P.C.
Subscribe to this Blog
New York
80 South Highland Ave
Ossining, NY 10562
914.941.5668
info@rfem.com
Washington, DC
607 14th St. NW
Suite 800
Washington, DC 20005
202.783.6040
info@rfem.com
Boston
10 Post Office Square
Suite 800
Boston, MA 02109
617.312.3101
info@rfem.com
RSS LinkedIn Twitter Facebook
Privacy PolicyDisclaimer

About Our Firm

To learn more about our firm and other practice areas, visit: www.rfem.com.

Rothwell Figg Blogs

  • Biosimilars Law Bulletin
  • Healthcare Marketing Law
  • Privacy Zone
  • PTAB Law Blog
  • Trademark Opposition Lawyer
Copyright © 2022, Rothwell, Figg, Ernst & Manbeck, P.C. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo

We use cookies to enhance your user experience. By continuing to use this site you are giving your consent for us to use cookies. For more information, please see our Privacy Policy.

Agree